Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14445068 | 0.89 | TSHR (0.52) | TSHRKDM4ESMN1; SMN2RECQLCASP2 | |
| SCHEMBL19155984 | 0.89 | MEN1 (0.43) | TSHRKDM4EMAPK1HIF1AADRA1A | |
| SCHEMBL12200765 | 0.88 | TSHR (0.47) | TSHRKDM4ESMN1; SMN2EPHX2RECQL | |
| SCHEMBL14031391 | 0.88 | TSHR (0.47) | TSHRKDM4EMAPK1HIF1AL3MBTL1 | |
| SCHEMBL21237600 | 0.88 | TSHR (0.47) | TSHRKDM4ESMN1; SMN2EPHX2RECQL | |
| SCHEMBL23267578 | 0.88 | TSHR (0.47) | TSHRSMN1; SMN2EPHX2RECQLCASP2 | |
| SCHEMBL19556855 | 0.88 | MEN1 (0.52) | TSHRSMN1; SMN2EPHX2RECQLCASP2 | |
| SCHEMBL22882753 | 0.88 | TSHR (0.61) | TSHRKDM4ESMN1; SMN2EPHX2RECQL | |
| SCHEMBL16995540 | 0.87 | TSHR (0.46) | TSHRKDM4EHIF1ASMN1; SMN2PAOX | |
| SCHEMBL17723057 | 0.86 | CASP2 (0.55) | TSHRKDM4EMAPK1HIF1AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896704-B2 | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230190616-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-10035820-B2 | Compounds which inhibit neuronal exocytosis | LUBRIZOL ADVANCED MATERIALS, INC (US) | 2018-07-31 | — | — | US | disclosed |
| US-9771392-B2 | Compounds which inhibit neuronal exocytosis | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9725483-B2 | Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions | LIPOTEC, S.A. (ES) | 2017-08-08 | — | — | US | disclosed |
| US-9511010-B2 | Compounds useful in the treatment and/or care of the skin, hair and/or mucous membranes and their cosmetic or pharmaceutical compositions | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9464129-B2 | Neuronal exocytosis inhibiting peptides | BCN PEPTIDES S.A. (ES) | 2016-10-11 | — | — | US | disclosed |
| US-9458194-B2 | Compounds useful in the treatment and/or care of the skin and their cosmetic or pharmaceutical compositions | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9393187-B2 | Peptide compounds that inhibit neuronal exocytosis | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160075738-A1 | COMPOUNDS USEFUL IN THE TREATMENT AND/OR CARE OF THE SKIN AND THEIR COSMETIC OR PHARMACEUTICAL COMPOSITIONS | LUBRIZOL ADVANCED MATERIALS, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20150140046-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | LUBRIZOL ADVANCED MATERIALS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150104485-A1 | COMPOUNDS FOR THE TREATMENT AND/OR CARE OF THE SKIN AND/OR MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150098989-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | LUBRIZOL ADVANCED MATERIALS, INC. | 2015-04-09 | — | — | US | disclosed |
| US-20150071974-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | LUBRIZOL ADVANCED MATERIALS, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8946154-B2 | Peptide ligands of somatostatin receptors | BCN PEPTIDES, S.A. (ES) | 2015-02-03 | — | — | US | disclosed |
| US-20130078295-A1 | SKIN ANTIAGING TREATMENT | LIPOTEC S.A. (ES) | 2013-03-28 | — | — | US | disclosed |
| US-20120122781-A1 | PEPTIDE LIGANDS OF SOMATOSTATIN RECEPTORS | BCN PEPTIDES, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
| US-20110305735-A1 | SKIN ANTIAGING TREATMENT | LIPOTEC, S.A. | 2011-12-15 | — | — | US | disclosed |
| US-20110206752-A1 | COMPOSITIONS FOR THE TREATMENT OF PAIN AND/OR INFLAMATION | BCN PEPTIDES, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| US-20100021510-A1 | NEURONAL EXOCYTOSIS INHIBITING PEPTIDES | LIPOTEC, S.A. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150098989-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | SLC18A2, SLC18A1, ATP6V1B2 | TSHR 4098/4885KDM4E 3358/4885MAPK1 2619/4885 |
| US-11896704-B2 | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | TYR, MTX1, MTX2 | TSHR 2085/4885KDM4E 1239/4885MAPK1 2575/4885 |
| US-20230190616-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | GLA, ALG3, ANXA6 | TSHR 1373/4885KDM4E 2766/4885MAPK1 2780/4885 |
| US-20160075738-A1 | COMPOUNDS USEFUL IN THE TREATMENT AND/OR CARE OF THE SKIN AND THEIR COSMETIC OR PHARMACEUTICAL COMPOSITIONS | CUTA, GLA, MC1R | TSHR 2613/4885KDM4E 955/4885MAPK1 2051/4885 |
| US-10035820-B2 | Compounds which inhibit neuronal exocytosis | SLC18A2, SLC18A1, ATP6V1B2 | TSHR 4098/4885KDM4E 3358/4885MAPK1 2619/4885 |
| US-20100021510-A1 | NEURONAL EXOCYTOSIS INHIBITING PEPTIDES | SNAP23, SNAP29, RABL3 | TSHR 1670/4885KDM4E 4082/4885MAPK1 2940/4885 |
| US-20130078295-A1 | SKIN ANTIAGING TREATMENT | SNAP23, MC1R, CUTA | TSHR 1263/4885KDM4E 3590/4885MAPK1 3497/4885 |
| US-20110305735-A1 | SKIN ANTIAGING TREATMENT | SNAP23, MC1R, CUTA | TSHR 1255/4885KDM4E 3735/4885MAPK1 3446/4885 |
| US-20120122781-A1 | PEPTIDE LIGANDS OF SOMATOSTATIN RECEPTORS | SSTR3, SSTR4, SSTR5 | TSHR 31/4885KDM4E 4841/4885MAPK1 3307/4885 |
| US-20150140046-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | SLC18A2, SLC18A1, ATP6V1B2 | TSHR 3772/4885KDM4E 3614/4885MAPK1 2965/4885 |
| US-20150104485-A1 | COMPOUNDS FOR THE TREATMENT AND/OR CARE OF THE SKIN AND/OR MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | MC1R, TYR, MC3R | TSHR 3407/4885KDM4E 4126/4885MAPK1 2598/4885 |
| US-20110206752-A1 | COMPOSITIONS FOR THE TREATMENT OF PAIN AND/OR INFLAMATION | IL1A, IL1B, IL1R1 | TSHR 1378/4885KDM4E 4880/4885MAPK1 2428/4885 |
| US-20150071974-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | SLC18A2, SLC18A1, ATP6V1B2 | TSHR 4022/4885KDM4E 3237/4885MAPK1 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.